Literature DB >> 32108349

Oncologic outcomes of segmentectomy vs lobectomy in pathologic stage IA (≤2 cm) invasive lung adenocarcinoma: A population-based study.

Feng Li1, Yue Zhao1, Ligong Yuan1, Shuaibo Wang1, Yousheng Mao1.   

Abstract

BACKGROUND AND OBJECTIVES: For early-stage invasive lung adenocarcinoma, it remains unclear whether segmentectomy can yield outcomes equivalent to those of lobectomy. This study aimed to compare survival outcomes after segmentectomy and lobectomy among patients with stage IA invasive lung adenocarcinoma.
METHODS: We identified patients with stage IA (≤2 cm) invasive lung adenocarcinoma who underwent segmentectomy or lobectomy from the Surveillance, Epidemiology, and End Results database (2004-2015). Propensity score matching (PSM) was used to balance the baseline characteristics. Overall survival (OS) and lung cancer-specific survival (LCSS) were compared using the Kaplan-Meier method and Cox proportional hazards regression.
RESULTS: A total of 5474 patients were included. Before PSM, the 5-year OS was 78.3% for patients undergoing lobectomy vs 76.5% for patients undergoing segmentectomy (P = .166) while LCSS were 86.8% vs 83.0% (P = .015). After PSM, survival analyses showed that segmentectomy had OS (75.8% vs 76.4%; P = .694) and LCSS (82.7% vs 82.9%; P = .604) equivalent to those of lobectomy. Cox regression demonstrated that segmentectomy was equivalent to lobectomy in terms of OS and LCSS before and after PSM.
CONCLUSION: For stage IA (≤2 cm) invasive lung adenocarcinoma, segmentectomy may have oncologic outcomes equivalent to those of lobectomy.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  invasive; lobectomy; lung adenocarcinoma; segmentectomy

Mesh:

Year:  2020        PMID: 32108349     DOI: 10.1002/jso.25880

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Three-dimensional computed tomography angiography and bronchography combined with three-dimensional printing for thoracoscopic pulmonary segmentectomy in stage IA non-small cell lung cancer.

Authors:  Wenbin Hu; Kang Zhang; Xiaoliang Han; Jiaming Zhao; Guzong Wang; Shunda Yuan; Binjun He
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

Review 3.  Current Surgical Indications for Non-Small-Cell Lung Cancer.

Authors:  Nathaniel Deboever; Kyle G Mitchell; Hope A Feldman; Tina Cascone; Boris Sepesi
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

4.  Establishment and Validation of a Predictive Nomogram for Postoperative Survival of Stage I Non-Small Cell Lung Cancer.

Authors:  Zhi-Hui Wang; Lili Deng
Journal:  Int J Gen Med       Date:  2022-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.